199 related articles for article (PubMed ID: 32787475)
41. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
42. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
43. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
44. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
[No Abstract] [Full Text] [Related]
45. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
46. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
47. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
49. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
50. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
51. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
[TBL] [Abstract][Full Text] [Related]
52. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Guo L; Wei R; Lin Y; Kwok HF
Front Immunol; 2020; 11():1508. PubMed ID: 32733486
[TBL] [Abstract][Full Text] [Related]
53. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
54. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
55. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
56. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
Saleh K; Khalifeh-Saleh N; Kourie HR
Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468
[No Abstract] [Full Text] [Related]
57. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.
Rocco D; Malapelle U; Del Re M; Della Gravara L; Pepe F; Danesi R; Troncone G; Gridelli C
Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):87-96. PubMed ID: 31978315
[No Abstract] [Full Text] [Related]
58. Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors.
Le CT; Murphy WJ
J Immunother Cancer; 2019 Nov; 7(1):291. PubMed ID: 31699145
[TBL] [Abstract][Full Text] [Related]
59. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer.
Wang L; Ma Q; Yao R; Liu J
Int Immunopharmacol; 2020 Feb; 79():106088. PubMed ID: 31896512
[TBL] [Abstract][Full Text] [Related]
60. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
Ma B; Akosman B; Kamle S; Lee CM; He CH; Koo JS; Lee CG; Elias JA
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
